Impact of different doses of rivaroxaban on clinical outcomes in elderly patients with non-valvular atrial fibrillation: a real-world study
Juan Yu, Zufeng Zhang, Qingru Yuan, Haobing Hu, Huimin Li, Meifang Huang, Youlin Mao · 2025
Read Impact of different doses of rivaroxaban on clinical outcomes in elderly patients with non-valvular atrial fibrillation: a real-world study by Juan Yu, Zufeng Zhang, Qingru Yuan, Haobing Hu, Huimin Li, Meifang Huang, Youlin Mao (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12723143.txt.
Description
Juan Yu and co-authors compare doses of the blood thinner rivaroxaban in older patients in this 2025 paper. The patients had non valvular atrial fibrillation, a heart rhythm problem that raises stroke risk. Doctors often lower the dose in older patients out of caution. Whether that helps or harms was the question.
Records covered 214 patients aged 65 and older treated at one hospital in Zhengzhou in 2022. Patients were split into a standard dose group and a low dose group. Outcomes were tracked for twelve months after discharge by records and phone calls. The low dose group was older on average. Stroke risk and bleeding risk scores were much the same in both groups at baseline.
Catalog record
| CREATOR | Juan Yu, Zufeng Zhang, Qingru Yuan, Haobing Hu, Huimin Li, Meifang Huang, Youlin Mao |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |